3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Classical hematology
2
Gastrointestinal
1
Conditions
Venous Thrombosis
2
Venous Thromboembolism
2
Pulmonary Embolism
2
Gastrointestinal Neoplasms
1
Interventions
Dalteparin
10
apixaban
9
Tinzaparin
4
Enoxaparin
4
Heparin, Low-Molecular-Weight
3
edoxaban
2
abelacimab
2
Rivaroxaban
2
MAA868
2
Dabigatran
2
perflutren
1
isoquercitrin
1
enoxaparin sodium
1
bemiparin
1
Warfarin
1
Sulfur Hexafluoride
1
Rosuvastatin Calcium
1
Hospitals
1
Fondaparinux
1
Fluorodeoxyglucose F18
1
Educational Status
1
Deoxyribonucleases
1
Acetylcysteine
1
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Pulmonary Embolism
×
abelacimab
×
Clear all
NCT05171075
2026-04-17
MAGNOLIA
Anthos Therapeutics, Inc.
Phase 3
Terminated
417 enrolled
NCT05171049
2026-02-23
ASTER
Anthos Therapeutics, Inc.
Phase 3
Terminated
1,150 enrolled